Welcome to the Stocktwits Top 25 Newsletter for Week 05 of 2024!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 05:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Standard and Poor's 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+5.49%) outperformed the S&P 500 index (+1.07%).
There were 8 major changes to the list this week.
The list of changes each week continues to shrink as the leaders settle into their positions. So far, technology and healthcare stocks are reestablishing their dominance after a record 2023.
Check out how the momentum meter has performed vs. the S&P 500 index this year:
Your Market Edge Unleashed:
Unleash your potential with our Edge subscription plan—bringing you unique social data, an ad-free experience, and more!
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+3.17%) outperformed the Nasdaq 100 index (+1.27%).
There were 4 major changes to the list this week.
The top of the Nasdaq 100 list continues to inhabit large and mega-cap technology stocks. As usual, the bottom of the list will continue to experience significant changes, given the large number of stocks returning 7-12% so far this year.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+21.23%) outperformed the Russell 2000 index (-0.79%).
There were 7 major changes to the list this week.
This list consists of biotech and healthcare names that some sort of catalyst has driven up. The biggest winners continue consolidating their recent gains and cementing their spot atop the list.
🐶🐶🐶
ST Top 25 TOP DAWG OF THE WEEK 🐶
The Top 25 lists’ Top Dawg was Atara Biotherapeutics, which rallied 103.33%. 📈
The small-cap biotechnology stock surged this week after the cell therapy developer said that The Lancet Oncology published data from its Phase 3 ALLELE study for its lead candidate tab-cel. Unlike other CAR-T cell therapies, there were no reports of adverse effects from this treatment, such as cytokine release syndrome. 🧪
$ATRA is up 139.22% YTD.
See Y’all Next Week 🤙
